Phase 1 VIR-5525 EGFR-directed T-cell engager trial.

This first-in-human study evaluates VIR-5525 as monotherapy and with pembrolizumab in dose-escalation and expansion cohorts for locally advanced or metastatic solid tumors expressing EGFR, including HNSCC, CRC, and NSCLC/CSCC. Sponsored by Vir Biotechnology, Inc., the trial assesses safety, pharmacokinetics, and preliminary anti-tumor activity.